TAPUR - Calfa, Carmen
-
Investigator:
Carmen Calfa
Email
Coordinator: Carolina Troche
+1 (305) 2431481
IRB: 20170529
SDG: Breast Cancer
Disease Site(s): Breast,Colon,Kaposis sarcoma,Kidney,Larynx,Liver,Lymphoid Leukemia,Multiple,Multiple Myeloma,Non-Hodgkin Lymphoma,Pancreas,Prostate,Soft Tissue
Sponsor: ASCO
Enrolling Sites:
Aventura
Deerfield
Gables
Kendall
Plantation
SylvesterTitle: The Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Eligibility Criteria - NCT02693535 *This information has been extracted from " www.clinicaltrials.gov"
20200056 - D'Amato Gina
-
Investigator:
Gina D'Amato
Email
Coordinator: Nailet Real Bestard
+1 (305) 2438173
IRB: 20200056
SDG: Bone and Soft Tissue Cancers
Disease Site(s): Anus,Bladder,Bones and Joints,Breast,Cervix Uteri,Colon,Esophagus,Kidney,Lip, Oral Cavity and Pharynx,Liver,Lung,Melanoma, skin,Other Digestive Organ,Other Urinary,Ovary,Prostate,Rectum,Small Intestine,Soft Tissue,Stomach,Thyroid
Sponsor: DECIPHERA
Enrolling Sites:
Sylvester
Title: A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor
Eligibility Criteria - NCT03069469 *This information has been extracted from " www.clinicaltrials.gov"
20201402 - Ezenwajiaku Nkiruka
-
Investigator:
Nkiruka Ezenwajiaku
Email
Coordinator:
IRB: 20201402
SDG: Stomach and Esophageal Cancer
Disease Site(s): Pancreas
Sponsor: ETCTN
Enrolling Sites:
Sylvester
Title: A Phase I study of Anetumab Ravtansine in Combination with either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
Eligibility Criteria - NCT03816358 *This information has been extracted from " www.clinicaltrials.gov"
20201359 - Hosein Peter
-
Investigator:
Peter Hosein
Email
Coordinator: Carla Montoya
IRB: 20201359
SDG: Stomach and Esophageal Cancer
Disease Site(s): Esophagus,Stomach
Sponsor: ETCTN
Enrolling Sites:
Deerfield
Gables
Plantation
SylvesterTitle: A Phase 2 Single-Arm Study of M6620 in Combination with Irinotecan in Patients with Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction Cancer
Eligibility Criteria - NCT03641313 *This information has been extracted from " www.clinicaltrials.gov"
20220046 - Hosein Peter
-
Investigator:
Peter Hosein
Email
Coordinator: Natalia Sanders Branca
+1 (305) 2433781
IRB: 20220046
SDG: Stomach and Esophageal Cancer
Disease Site(s): Stomach
Sponsor: ETCTN
Enrolling Sites:
Aventura
Deerfield
Gables
Kendall
Plantation
SylvesterTitle: A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) with or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers
Eligibility Criteria - NCT04941287 *This information has been extracted from " www.clinicaltrials.gov"
MATCH - Huang, Marilyn
-
Investigator:
Marilyn Huang
Email
Coordinator: Carolina Troche
+1 (305) 2431481
IRB: 20150671
SDG: Gynecologic Cancer
Disease Site(s): Cervix Uteri,Colon,Corpus Uteri,Kaposis sarcoma,Kidney,Larynx,Liver,Multiple Myeloma,Non-Hodgkin Lymphoma,Other Female Genital,Ovary,Pancreas,Prostate,Soft Tissue
Sponsor: ECOG
Enrolling Sites:
Coral Springs
Deerfield
Gables
Hollywood
Kendall
Plantation
SylvesterTitle: Molecular Analysis for Therapy Choice (MATCH)
Eligibility Criteria - NCT02465060 *This information has been extracted from " www.clinicaltrials.gov"
RTX-240-01 - Merchan, Jaime
-
Investigator:
Jaime Merchan
Email
Coordinator: Isabel Fernandez
+1 (305) 2435486
IRB: 20200686
SDG: Prostate, Bladder, and Kidney Cancers
Disease Site(s): Multiple
Sponsor: Rubius Therapeutics
Enrolling Sites:
Sylvester
Title: PHASE 1/2 STUDY OF RTX-240 AS A MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB
Eligibility Criteria - NCT04372706 *This information has been extracted from " www.clinicaltrials.gov"
Tbio-6517-ITu-001 - Pimentel, Agustin
-
Investigator:
Agustin Pimentel
Email
Coordinator: Rakhi Modak
+1 (305) 2437387
IRB: 20200277
SDG: Colorectal Cancer
Disease Site(s): Multiple
Sponsor: TSB
Enrolling Sites:
Sylvester
Title: A Phase 1/2a, Multicenter, Open-label Trial of TBio-6517, an Oncolytic Vaccinia Virus, Administered Alone and in Combination with Pembrolizumab, in Patients with Advanced Solid Tumors
Eligibility Criteria - NCT04301011 *This information has been extracted from " www.clinicaltrials.gov"
20220162 - Spieler Benjamin
-
Investigator:
Benjamin Spieler
Email
Coordinator: Zaida Abreu
+1 (305) 2434243
IRB: 20220162
SDG: Stomach and Esophageal Cancer
Disease Site(s): Esophagus
Sponsor: NRG
Enrolling Sites:
Deerfield
Gables
SylvesterTitle: Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer
Eligibility Criteria - NCT03801876 *This information has been extracted from " www.clinicaltrials.gov"
SPN-00714 - Valdes, Frances
-
Investigator:
Frances Valdes
Email
Coordinator: Yanel Diaz Caro
3052438227
IRB: 20190673
SDG: Other
Disease Site(s): Breast,Colon,Esophagus,Kidney,Lung,Other Female Genital,Ovary,Stomach
Sponsor: MTEM
Enrolling Sites:
Sylvester
Title: A Phase 1 open-label, multicenter dose escalation study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors
Eligibility Criteria - NCT04029922 *This information has been extracted from " www.clinicaltrials.gov"